Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALEC logo

Alector Inc (ALEC)ALEC

Upturn stock ratingUpturn stock rating
Alector Inc
$2.59
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/29/2024: ALEC (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -72.7%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 19
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/29/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -72.7%
Avg. Invested days: 19
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/29/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 253.65M USD
Price to earnings Ratio -
1Y Target Price 10.28
Dividends yield (FY) -
Basic EPS (TTM) -1.71
Volume (30-day avg) 1136440
Beta 0.66
52 Weeks Range 2.37 - 8.90
Updated Date 12/1/2024
Company Size Small-Cap Stock
Market Capitalization 253.65M USD
Price to earnings Ratio -
1Y Target Price 10.28
Dividends yield (FY) -
Basic EPS (TTM) -1.71
Volume (30-day avg) 1136440
Beta 0.66
52 Weeks Range 2.37 - 8.90
Updated Date 12/1/2024

Earnings Date

Report Date 2024-11-05
When BeforeMarket
Estimate -0.53
Actual -0.43
Report Date 2024-11-05
When BeforeMarket
Estimate -0.53
Actual -0.43

Profitability

Profit Margin -257.54%
Operating Margin (TTM) -301.32%

Management Effectiveness

Return on Assets (TTM) -19.25%
Return on Equity (TTM) -112.55%

Revenue by Products

Valuation

Trailing PE -
Forward PE 526.32
Enterprise Value -168917554
Price to Sales(TTM) 4.12
Enterprise Value to Revenue 2.38
Enterprise Value to EBITDA -8.4
Shares Outstanding 97932600
Shares Floating 82150766
Percent Insiders 10.08
Percent Institutions 86.07
Trailing PE -
Forward PE 526.32
Enterprise Value -168917554
Price to Sales(TTM) 4.12
Enterprise Value to Revenue 2.38
Enterprise Value to EBITDA -8.4
Shares Outstanding 97932600
Shares Floating 82150766
Percent Insiders 10.08
Percent Institutions 86.07

Analyst Ratings

Rating 4.18
Target Price 13.78
Buy 2
Strong Buy 6
Hold 2
Sell 1
Strong Sell -
Rating 4.18
Target Price 13.78
Buy 2
Strong Buy 6
Hold 2
Sell 1
Strong Sell -

AI Summarization

Alector Inc. - Comprehensive Stock Analysis:

Company Profile:

History and Background: Alector, Inc., was founded in 2009. The company initially focused on developing therapies for neurodegenerative diseases such as Alzheimer's disease. However, in 2018, it shifted its focus to immuno-neurology, aiming to develop new drugs for inflammatory and neurodegenerative diseases of the central nervous system.

Core Business Areas: Alector currently focuses on three primary business areas:

  • Immuno-neurology: Developing therapies for diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), caused by immune system dysfunction in the central nervous system.
  • Neuroinflammation: Targeting neuroinflammation, a key contributor to various neurological conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
  • Immune modulation: Modulating the immune system to treat diseases beyond the central nervous system.

Leadership and Corporate Structure: Alector has a diverse leadership team with expertise in drug development, neuroscience, and business management. Some key figures include:

  • CEO and President: Arnon Rosenthal, Ph.D.: Leads the company with over two decades of experience in the pharmaceutical industry.
  • Chief Scientific Officer: Christopher Proudfoot, Ph.D.: Oversees all research and development efforts with extensive experience in immunology and neuroscience.
  • Chief Medical Officer: Michael Panzara, M.D.: Oversees all clinical development programs and has significant experience in clinical research and drug development.

Top Products and Market Share: Alector currently has no marketed products. However, their lead candidate, AL001, is under development for FTD and ALS. This is an anti-inflammatory monoclonal antibody targeting triggering receptor expressed on myeloid cells 2 (TREM2). AL001 is currently in Phase 3 clinical trials for FTD and Phase 2/3 trials for ALS.

Market Share Analysis: While Alector has no current market share due to no marketed products, the market for FTD treatments is estimated to reach $3 billion by 2025, while the ALS market is valued at around $3.5 billion in the same year. Alector faces competition from companies like Biogen and UCB, who also have drugs in development for these conditions.

Total Addressable Market (TAM): Alector's TAM is the total market for the diseases they aim to treat. This includes:

  • FTD: Approximately 50,000 diagnosed cases in the US
  • ALS: Estimated 30,000 diagnosed cases in the US
  • Other Neuroinflammatory Conditions: This market is much larger, encompassing diseases like Alzheimer's, Parkinson's, and multiple sclerosis, with millions of patients worldwide.

Financial Performance: As of the most recent quarterly report, Alector reported:

  • Revenue: $0 million
  • Net Loss: $54.3 million
  • Cash and Cash Equivalents: $445.4 million
  • Cash Burn Rate: Approximately $35 million per quarter

Year-over-Year Performance: Alector's net loss has increased year-over-year, primarily due to rising research and development expenses. Cash burn rate also remains high due to clinical trial activities.

Dividends and Shareholder Returns: Alector does not currently pay dividends, as it is in the early stages of development and focused on investing in research and development. Total shareholder returns have been negative in recent years due to the company's pre-revenue status and lack of marketed products.

Growth Trajectory: Alector's future growth depends on the success of its clinical trials and the potential commercialization of its lead candidate, AL001. Positive results from clinical trials could lead to significant stock price appreciation, while regulatory setbacks or failures could have a negative impact.

Market Dynamics: The market for treatments of neurodegenerative and neuroinflammatory diseases is growing rapidly due to the aging population and increasing demand for new therapeutic options. However, this market is highly competitive, with many pharmaceutical and biotechnology companies vying for market share.

Continued below

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Alector Inc

Exchange NASDAQ Headquaters South San Francisco, CA, United States
IPO Launch date 2019-02-07 Co-Founder, CEO & Director Dr. Arnon Rosenthal Ph.D.
Sector Healthcare Website https://www.alector.com
Industry Biotechnology Full time employees 241
Headquaters South San Francisco, CA, United States
Co-Founder, CEO & Director Dr. Arnon Rosenthal Ph.D.
Website https://www.alector.com
Website https://www.alector.com
Full time employees 241

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​